Pathos AI, Alphamab in $2B+ deal for TROP2/HER3 ADC

AI Briefing

• – • Pathos AI and Alphamab are in a $2 billion+ deal for TROP2/HER3 ADC.
• – • The ADC is being developed for the treatment of certain types of cancer.
• – • Terms of the deal were not disclosed in the preview.